The Diagnostic Research Industry is playing an integral part in the medical evaluation and treatment of patients.  This industry is vital to the healthcare market as it is providing information related to the severity and causes of illnesses in patients to healthcare practitioners. The changes we are witnessing in today’s healthcare industry are setting the goal for evolution we will see over the next decade.

There are major drivers that are changing and will change the direction of this industry in present and future as well. The first driver is technology. As time passes by, new technologies are emerging and playing a very important role in the healthcare industry. In today’s world, patients want easier access to care and demand better service. The demand for this industry is linked to the number of patients receiving the treatment. The profitability and growth of the company depend on good marketing and efficient operations.

Let check these 15 companies in Diagnostic Research Industry to know more about this industry and the trends this industry is following:

Interpace Biosciences Inc. (NASDAQ: IDXG)

Interpace Biosciences Inc. (NASDAQ: IDXG) shares were trading up 32.89% at $3.96 at the time of writing on Wednesday. Interpace Biosciences Inc. (NASDAQ: IDXG) share price went from a low point around $2.57 to briefly over $11.00 in the past 52 weeks, though shares have since pulled back to $3.96. IDXG market cap has remained high, hitting $15.88M at the time of writing, giving it a price-to-sales ratio of more than 0.

Interpace Biosciences Inc. (NASDAQ: IDXG) has announced that the Audit Committee has disclosed the result of an independent investigation. The committee has completed the investigation with the statement that the allegations made in the complaints were unverified and there is no truth behind them. investigation and If we look at the recent analyst rating IDXG, Janney initiated coverage on IDXG shares with a Buy rating.

OPKO Health Inc. (NASDAQ: OPK)

OPKO Health Inc. (NASDAQ: OPK) last closed at $4.07, in a 52-week range of $1.12 to $6.47. Analysts have a consensus price target of $8.00. OPKO Health Inc. (OPK) disclosed it plans to report operating and financial results for the three months ended September 30, 2020, as well as discuss financial guidance, after the close of the U.S. financial markets on Thursday, October 29, 2020.

Invitae Corporation (NYSE: NVTA)

Invitae Corporation (NYSE: NVTA) stock drop by -6.29% to $49.28. The most recent rating by JP Morgan, on October 14, 2020, is at a Neutral. Invitae Corporation (NVTA) disclosed that on October 2, 2020, it has executed the transaction to bring ArcherDX into Invitae to create a comprehensive offering that provides testing services for disease risk, therapy optimization, and personalized cancer monitoring to enable precision approaches to cancer treatment.

Pacific Biosciences of California Inc. (NASDAQ: PACB)

Pacific Biosciences of California Inc. (NASDAQ: PACB) shares headed rising, higher as much as 0.07%. The most recent rating by JP Morgan, on October 02, 2020, is at an Overweight. Pacific Biosciences of California Inc. (PACB) has disclosed that collaborated with Children’s Mercy Kansas City to further understand the most challenging pediatric diseases. The companies will join forces to sequence a statistically significant cohort of rare disease cases for which previous whole-genome and whole-exome sequencing studies yielded no answers.

Bionano Genomics Inc. (NASDAQ: BNGO)

Bionano Genomics Inc. (NASDAQ: BNGO) fall -0.15% after losing more than $0.0 on Wednesday. Bionano Genomics Inc. (BNGO) revealed today that it is scheduled to release financial results of the third quarter ended September  30, 2020, on November 12, 2020. The company will also hold the conference call on the same day.

T2 Biosystems Inc. (NASDAQ: TTOO)

T2 Biosystems Inc. (NASDAQ: TTOO) stock drop by 0.00% to $1.33 after T2 Biosystems to Report Third Quarter 2020 Financial Results on November 4, 2020. The most recent rating by BTIG Research, on October 08, 2020, is at a Buy.  T2 Biosystems Inc. (TTOO) market capitalization has remained high, hitting $196.79 million at the time of writing.

NeoGenomics Inc. (NASDAQ: NEO)

NeoGenomics Inc. (NASDAQ: NEO) Shares headed rising, higher as much as 5.46%. The most recent rating by Morgan Stanley, on September 09, 2020, is at an Overweight. NeoGenomics Inc. (NEO) revealed its plans to open a state-of-the-art research laboratory in China in association with the new lab PPD, Inc. (NASDAQ: PPD) is opening in Suzhou.

PerkinElmer Inc. (NYSE: PKI)

PerkinElmer Inc. (NYSE: PKI) fall -2.10% after losing more than -$2.62 on Wednesday. PerkinElmer Inc. (PKI) earlier announced that it is expected to report organic revenue growth of approximately 35% and 33%, respectively, for the third quarter ended October 4, 2020.

Chembio Diagnostics Inc. (NASDAQ: CEMI)

Chembio Diagnostics Inc. (NASDAQ: CEMI) last closed at $4.77, in a 52-week range of $2.25 to $15.89. Analysts have a consensus price target of $5.00. Chembio Diagnostics Inc. (CEMI) disclosed earlier that the U.S. Food and Drug Administration (FDA) has approved the Premarket Approval (PMA) application for the DPP HIV-Syphilis System.

Illumina Inc. (NASDAQ: ILMN)

Illumina Inc. (NASDAQ: ILMN) Shares headed falling, lower as much as -4.35%. The most recent rating by Guggenheim, on October 13, 2020, is at a Neutral. Illumina Inc. (ILMN) has earlier announced that it is scheduled to release the third quarter 2020 following the close of the market on Thursday, October 29, 2020.

Enzo Biochem Inc. (NYSE: ENZ)

Enzo Biochem Inc. (NYSE: ENZ) fall -17.24% after losing more than -$0.45 on Wednesday. Enzo Biochem Inc. (ENZ) earlier reported financial results for the fourth quarter and full-year ended July 31, 2020, and provided a business update on recent corporate and operational developments.

Fulgent Genetics Inc. (NASDAQ: FLGT)

Fulgent Genetics Inc. (NASDAQ: FLGT) last closed at $38.17, in a 52-week range of $6.70 to $52.47. Analysts have a consensus price target of $56.25. Fulgent Genetics Inc. (FLGT) disclosed earlier that the Ohio Department of Rehabilitation and Correction (“ODRC”) has selected Fulgent Genetics for their COVID-19 testing needs.

QIAGEN N.V. (NYSE: QGEN)

QIAGEN N.V. (NYSE: QGEN) stock drop by -0.11% to $52.37. The most recent rating by BofA Securities, on October 06, 2020, is at a Buy. QIAGEN N.V. (QGEN) earlier announced preliminary sales and adjusted earnings per share (EPS) results for the third quarter of 2020. It has shared that the Net sales grew 26% at actual rates, and also rose 26% at constant exchange rates (CER) $481.3 million from $382.7 million in the same period of 2019.

Fluidigm Corporation (NASDAQ: FLDM)

Fluidigm Corporation (NASDAQ: FLDM) last closed at $6.89, in a 52-week range of $1.17 to $12.45. Fluidigm Corporation (FLDM) has moved up 488.03% from its 52-weeks low and moved down -44.74% from its 52-weeks high. Looking at its liquidity, it has a current ratio of $509.65 million at the time of writing.

Danaher Corporation (NYSE: DHR)

Danaher Corporation (NYSE: DHR) stock soar by 0.41% to $226.55. The most recent rating by Wolfe Research, on June 16, 2020, is at an Outperform. Danaher Corporation (DHR) share price went from a low point around $119.60 to briefly over $227.48 in the past 52 weeks, though shares have since pulled back to $222.59. DHR  market cap has remained high, hitting $156.91 billion at the time of writing.